Transplant/Artificial Liver
Liver Transplant - HCV
EASL 2013: Triple Therapy for Hepatitis C Is Effective after Liver Transplantation but Comes with Side Effects
- Details
- Category: HCV Treatment
- Published on Friday, 10 May 2013 00:00
- Written by Liz Highleyman
Adding the approved HCV protease inhibitor telaprevir (Incivek or Incivo) to pegylated interferon and ribavirin can increase sustained response rates even for difficult-to-treat liver transplant recipients, but adverse events are common, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.
Milk Thistle Drug May Help Control HCV Replication after Liver Transplant
- Details
- Category: HCV Treatment
- Published on Thursday, 28 February 2013 00:00
- Written by Liz Highleyman
Silibinin, a medication derived from the milk thistle plant, lowered hepatitis C virus (HCV) levels in patients awaiting liver transplantation in a pilot study, which may help reduce the risk of HCV recurrence in the new liver, Spanish researchers reported in the March 2013 Journal of Hepatology.
Researchers Grow Liver Tissue from Pluripotent Stem Cells
- Details
- Category: Liver Transplant - HBV
- Published on Friday, 22 June 2012 00:00
- Written by Liz Highleyman
Japanese researchers have produced liver-like tissue from induced pluripotent stem cells in the laboratory that can process drugs like a human liver, according to a presentation at the 10th annual meeting of the International Society for Stem Cell Research last week in Yokohama.
Everolimus (Zortress) Approved to Prevent Liver Transplant Rejection
- Details
- Category: Liver Transplant - HBV
- Published on Wednesday, 20 February 2013 00:00
- Written by Novartis
The U.S. Food and Drug Administration (FDA) this month approved the immunosuppressant drug everolimus (brand name Zortress) for preventing organ rejection in people who undergo liver transplantation. A recent large study found that everolimus was easier on the kidneys when used in combination with low-dose tacrolimus (Prograf).
Changes Proposed for Allocation of Donated Livers
- Details
- Category: Liver Transplant - HBV
- Published on Thursday, 01 September 2011 00:00
- Written by Wiley-Blackwell
For some patients transplantation is the only treatment for advanced liver disease due to chronic hepatitis B, hepatitis C, liver cancer, alcoholism, or other causes. But the supply of donor livers does not meet the demand, meaning that many people die while on a waiting list. As described in the September 2011 issue of Liver Transplantation, experts have been meeting for the past 2 years to develop a modified allocation system that aims to reduce wait-list mortality.
More Articles...
- IAS 2011: Transplants Safe for HIV+ People but HCV Adds Risk
- Treatment of Recurrent Hepatitis C after Liver Transplantation
- Artificial Liver Device Improves Survival for Hepatitis B and C Patients with Decompensated Disease
- HIV Coinfection Does Not Worsen Liver Transplant Outcomes in People with Hepatitis B or C
Web Design and Development by